companies eli-lilly-co 
IP Law 360
OCTOBER 4, 2022
Drugmakers Eli Lilly and Co. and Teva Pharmaceuticals must take their patent dispute over rival migraine medications to a jury, a Massachusetts federal judge said Monday, denying the bulk of the companies' dueling motions for summary judgment.
LexBlog IP
OCTOBER 18, 2023
. (“Meitheal”) has entered into an exclusive licensing deal with Tonghua Dongbao Pharmaceutical Co., The agreement grants Meitheal and its parent company, Nanjing King-Friend Biochemical Pharmaceutical Co., THDB and NKF will jointly handle product development and supply.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
LexBlog IP
DECEMBER 23, 2021
On Monday the FDA approved Eli Lilly’s insulin glargine biosimilar Rezvoglar, a biosimilar to Sanofi’s Lantus. Lannett Company, Inc. Lannett is co-developing the product with partners within the HEC Group of companies. Rezvoglar is the second Lantus biosimilar insulin product approved in the U.S.,
Patently-O
OCTOBER 5, 2022
Courts to obtain discovery in order to facilitate foreign litigation; with the pending global litigation between Eli Lilly and Novartis serving as our key example. One quirk is that the Novartis patents were not developed alongside the company’s Cosentyx product. In 2021, Lilly brought the case to the U.S.
Bio Law Blog
APRIL 28, 2020
While existing antivirals and anti-inflammatory drugs are undergoing clinical testing against COVID-19 now , biopharmaceutical companies are taking a variety of approaches to develop new therapies. These come from stem cell-focused companies, including Hope Biosciences , Celltex and Athersys.
Fish & Richardson Trademark & Copyright Thoughts
NOVEMBER 13, 2020
7] If a branded company initiates an infringement action against a generic company within 45 days of receiving notice of ANDA submission, this triggers a 30-month stay during which FDA cannot issue a final approval for the ANDA. [8] If a branded company gets venue wrong, it risks a motion to dismiss for improper venue.
Bio Law Blog
APRIL 15, 2020
Generally, viruses penetrate a host cell, co-opt the host-cell machinery to replicate their genome, assemble new viruses and then escape the cell to spread the infection. Drug repurposing is being aggressively pursued by the biopharmaceutical industry. Antiviral drugs aim to interrupt some part of the viral life cycle.
Expert insights. Personalized for you.
40 
Let's personalize your content